Search research articles
Contact Us
Filters
Showing results (31-40 of 47) with videos related to
Page
of 5
Sort By:
Respiratory Medicine
|
July 26, 2014
A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD
Dean Quinn, J P Seale, Colin Reisner, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
August 22, 2020
The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline
Marjan Kerkhof, Jaco Voorham, Paul Dorinsky, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
July 4, 2024
Albuterol-budesonide rescue reduces progression from asthma deterioration to severe exacerbation
Bradley E Chipps, Alberto Papi, Richard Beasley, et al.
The Lancet. Respiratory Medicine
|
September 21, 2018
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Gary T Ferguson, Klaus F Rabe, Fernando J Martinez, et al.
Current Medical Research and Opinion
|
August 16, 2023
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT
Daiana Stolz, Erik Hermansson, Mario Ouwens, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 30, 2017
Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study
Sanjay Sethi, Charles Fogarty, Nicola A Hanania, et al.
Respiratory Medicine
|
October 13, 2019
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol
Klaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 31, 2017
Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study
Sanjay Sethi, Charles Fogarty, Nicola A Hanania, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 30, 2020
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study
Fernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
The New England Journal of Medicine
|
June 25, 2020
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Klaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 47) with videos related to
Sort By:
Page
of 5
Respiratory Medicine
|
July 26, 2014
A randomized study of formoterol fumarate in a porous particle metered-dose inhaler in patients with moderate-to-severe COPD
Dean Quinn, J P Seale, Colin Reisner, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
August 22, 2020
The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline
Marjan Kerkhof, Jaco Voorham, Paul Dorinsky, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
July 4, 2024
Albuterol-budesonide rescue reduces progression from asthma deterioration to severe exacerbation
Bradley E Chipps, Alberto Papi, Richard Beasley, et al.
The Lancet. Respiratory Medicine
|
September 21, 2018
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial
Gary T Ferguson, Klaus F Rabe, Fernando J Martinez, et al.
Current Medical Research and Opinion
|
August 16, 2023
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT
Daiana Stolz, Erik Hermansson, Mario Ouwens, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 30, 2017
Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study
Sanjay Sethi, Charles Fogarty, Nicola A Hanania, et al.
Respiratory Medicine
|
October 13, 2019
A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol
Klaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
August 31, 2017
Erratum: Erratum: Efficacy of Formoterol Fumarate Delivered by Metered Dose Inhaler Using Co-Suspension™ Delivery Technology Versus Foradil® Aerolizer® in Moderate-To-Severe COPD: A Randomized, Dose-Ranging Study
Sanjay Sethi, Charles Fogarty, Nicola A Hanania, et al.
American Journal of Respiratory and Critical Care Medicine
|
November 30, 2020
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study
Fernando J Martinez, Klaus F Rabe, Gary T Ferguson, et al.
The New England Journal of Medicine
|
June 25, 2020
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Klaus F Rabe, Fernando J Martinez, Gary T Ferguson, et al.
Page
of 5